Key facts
- This page summarizes Jonathan D. Root's Form 4 filing for Inari Medical, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 19 Feb 2025, 20:14.
Jonathan D. Root - 19 Feb 2025 Form 4 Insider Report for Inari Medical, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 19 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Feb 2025, 20:14:58 UTC
- Prior SEC filing
- 12 Jun 2024
- Next SEC filing
- 05 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shannon Trevino, attorney-in-fact for Jonathan Root, M.D.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan D. Root filed Form 4 for Inari Medical, Inc. on 19 Feb 2025.
Change
- Previous filing in this sequence was filed on 12 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NARI
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -541,149
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
NARI
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -335
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Feb 2025
- Ownership
- Directly Owned by Spouse
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jonathan D. Root is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
Footnote F2
Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.